Daptomycin dosing in obese patients: analysis of the use of adjusted body weight versus actual body weight

BACKGROUND: Food and Drug Administration–approved daptomycin dosing uses actual body weight, despite limited dosing information for obese patients. Studies report alterations in daptomycin pharmacokinetics and creatine phosphokinase elevations associated with higher weight-based doses required for o...

Descripción completa

Detalles Bibliográficos
Autores principales: Fox, Ashley N., Smith, Winter J., Kupiec, Katherine E., Harding, Stephanie J., Resman-Targoff, Beth H., Neely, Stephen B., White, Bryan P., Owens, Ryan E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354309/
https://www.ncbi.nlm.nih.gov/pubmed/30728962
http://dx.doi.org/10.1177/2049936118820230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354309/
https://www.ncbi.nlm.nih.gov/pubmed/30728962
http://dx.doi.org/10.1177/2049936118820230

Ejemplares similares